The IM-ZBULLE Study : " Z-track " and " Airlock " Techniques During Intramuscular Injection of Haloperidol Decanoate

Sponsor
Centre Hospitalier St Anne (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05995457
Collaborator
Groupe Hospitalier Paul Guiraud (Other), Etablissement Public de Santé Barthélemy Durand (Other)
84
1
2
15
5.6

Study Details

Study Description

Brief Summary

Intramuscular injection (IMI) is the process of administering a drug treatment into muscle tissue. The transmission of skills in this care practice is essentially based on the experience of peers. In France, there are no official guidelines for this technical procedure.

Haloperidol decanoate is widely used in psychiatry. This long-acting antipsychotic treatment considerably reduces the risk of relapse and hospitalization. It is administered by IMI. This treatment is invasive, painful and risks complications for the patient. Nurses must ensure that the treatment is as painless as possible, and adapt their practice in line with current recommendations.

Among the various IMI techniques available, the "Z-track" and the "Airlock" limit leakage into subcutaneous tissues when the needle is withdrawn, by locking the active product into the muscular tissues. According to an exploratory study (n=303), 73% of nurses observe active product leakage after injections, and 89% of nurses are not familiar with either the "Z-track" or "Airlock" techniques.

Many foreign studies have been carried out to demonstrate the relevance of these techniques, particularly in terms of pain reduction during treatment, but the results have yet to be confirmed.

The investigators hypothesize that the combined use of the "Z-track" and "Airlock" techniques during intramuscular injection of Haloperidol decanoate is more effective in reducing patient pain than usual practice.

Condition or Disease Intervention/Treatment Phase
  • Other: Intramuscular injection of Haloperidol decanoate using the "Z-track" and "Airlock" techniques
  • Other: Intramuscular injection of Haloperidol decanoate using standard techniques
N/A

Detailed Description

This is a multicenter, prospective, randomized, double-blind, controlled, study in 2 parallel groups.

Experimental and control administration protocols will be standardized to harmonize injection practices between the different nurses providing care, and to control some variables. Nurses will have been trained in these protocols and in experimental injection techniques.

The experimental group will be offered an intramuscular injection using the "Z-track" and "Airlock" techniques, while the control group will have an "usual" injection.

An intermediate analysis of futility and efficacy is planned once 50% of the planned sample has completed the study.

The object of the research is the intramuscular injection procedure - Product injected:

haloperidol decanoate (Haldol Decanoas®).

Study Design

Study Type:
Interventional
Anticipated Enrollment :
84 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double (Participant, Investigator)
Masking Description:
Advanced practice nurses (APNs) will carry out clinical examinations before and after the treatment. They will not be present during the treatment, and the patient will not know the technique used, in order to ensure a double-blind evaluation. Only the nurses performing the injection will be aware of the technique used (experimental or control).
Primary Purpose:
Other
Official Title:
Efficacy of the Combination of " Z-track " and " Airlock " Techniques During Intramuscular Injection of Haloperidol Decanoate in Adult Patients With Schizophrenic or Related Disorder : A Multicenter Randomized Controlled Trial
Anticipated Study Start Date :
Sep 1, 2023
Anticipated Primary Completion Date :
Sep 30, 2024
Anticipated Study Completion Date :
Nov 30, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: Intramuscular injection of Haloperidol decanoate using the "Z-track" and "Airlock" techniques

Intramuscular injection involves administering the drug treatment Haloperidol decanoate into muscle tissue using the "Z-track" and "Airlock" techniques.

Other: Intramuscular injection of Haloperidol decanoate using the "Z-track" and "Airlock" techniques
Intramuscular injection involves administering the drug treatment Haloperidol decanoate into muscle tissue using the "Z-track" and "Airlock" techniques

Other: Control arm, Intramuscular injection as usual

Intramuscular injection involves administering the drug Haloperidol decanoate into muscle tissue using the usual technique

Other: Intramuscular injection of Haloperidol decanoate using standard techniques
Intramuscular injection involves administering the drug Haloperidol decanoate into muscle tissue using the usual technique.

Outcome Measures

Primary Outcome Measures

  1. pain reduction [Day 0 intervention day]

    To evaluate the efficacy of combining the "Z-track" and "Airlock" techniques concerning reducing pain in adult patients treated with Haloperidol decanoate. The primary outcome measure is pain reduction, assessed using a millimeter-scale visual analogic scale (VAS) to measure pain perceived by the patient 5 minutes after the treatment.

Secondary Outcome Measures

  1. Drug leakage reduction [Day 0 intervention day]

    To measure the loss (leakage) of active product when the needle is withdrawn : The outcome measure is a reduction in the loss of active product by assessing the diameter (using a millimeter scale) of active product that flow back through the puncture site using an absorbent pad.

  2. Impact of the injection [Day 0 to Day 3]

    To measure the impact of combining the "Z-track" and "Airlock" techniques on potential complications related to treatment : The outcome measure is the reduction in signs of secondary complications, as measured by a pre- and post-injection clinical examination and a phone call to the patient between Day 1 and Day 3.

  3. Improving participants satisfaction [Day 14 or Day 21 or Day 28 depending to the frequency established by the prescription1]

    To measure overall patient satisfaction with the combination of "Z-track" and "Airlock" intramuscular injection techniques. The outcome measure is participant satisfaction, assessed using Attkisson's CSQ-8 questionnaire.

  4. Improving the therapeutic alliance [Day 0 (intervention day) and Day 14 or Day 21 or Day 28 depending to the frequency established by the prescription]

    To measure therapeutic alliance during follow-up :The outcome measure is the overall therapeutic alliance score, using the Working Alliance Inventory (WAI) scale before and after intervention

  5. Identifying the obstacles and levers to changing practices [During 14 Months]

    To identify the levers and obstacles to nurses' change of practice : The outcome measure is the identification of levers and obstacles to change in professional practice among psychiatric nurses, by means of a complementary qualitative descriptive study.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Adult ;

  • having an outpatient treatment in a Mental Health Community Center ("Centre Médico-Psychologique" CMP in french) ;

  • with an CIM-10 diagnosis between F20-F29 (Schizophrenia, schizotypal disorder and delusional disorders);

  • communicative and able to give free and informed consent to the study;

  • prescribed Haloperidol decanoate;

  • covered by the french social security

Exclusion Criteria:
  • Minor ;

  • pregnant women ;

  • with insufficient understanding of the French language to understand the VAS;

  • suffering from any of the following known somatic comorbidity : coagulation disorder, leucopenia, immunosuppression;

  • currently prescribed treatment: immunosuppressant, anticoagulant, antibiotic, antiretroviral, other products administered by IMI at dorsogluteal injection sites (antibiotic therapy, hormone therapy, vitamin therapy).

Contacts and Locations

Locations

Site City State Country Postal Code
1 Rayan BCHINI Villejuif France 94800

Sponsors and Collaborators

  • Centre Hospitalier St Anne
  • Groupe Hospitalier Paul Guiraud
  • Etablissement Public de Santé Barthélemy Durand

Investigators

  • Principal Investigator: Rayan BCHINI, GHU Paris Psychiatrie & Neurosciences

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Centre Hospitalier St Anne
ClinicalTrials.gov Identifier:
NCT05995457
Other Study ID Numbers:
  • D23-P001
First Posted:
Aug 16, 2023
Last Update Posted:
Aug 16, 2023
Last Verified:
Aug 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Centre Hospitalier St Anne
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 16, 2023